With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.
RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...
With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
Six companies, including Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX), are set to join the Nasdaq 100 ...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results